ALNYLAM PHARMACEUTICALS, INC. (ALNY) Form 8-K — May 27, 2026
$ALNYForm 8-KItems 5.02, 5.07, 9.01Filed May 27, 2026, 4:30 PM ET0001628280-26-038499Original filing
Alnylam Pharmaceuticals expanded its Board of Directors from ten to eleven members, electing Benjamin F. Cravatt, Ph.D., as a new Class III director effective June 1, 2026. Dr. Cravatt will serve on the Science and Technology Committee and receive an annual cash retainer of $75,000 plus an initial stock option grant valued at $600,000.
Key figures
- Shares Outstanding
- 133427910
- Board size new
- 11
- Board size prior
- 10
- Director retainer annual
- 75000
- Initial stock option value
- 600000
Price after filing
1 day: +3.2%7 days: -1.0%30 days: -0.8%
Close on the filing date to close N calendar days later (from $295.63). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.